A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations
This study tests a new experimental medication called IAM1363 for people with advanced cancers that have a specific protein change called HER2. Researchers want to find out the safest dose and see how well this treatment works against different types of cancer, including breast, lung, and stomach cancers.
You may be able to join if you are 18 or older, have an advanced cancer with a HER2 change that has progressed after previous treatments, and are well enough to handle daily activities. People with certain untreated heart conditions, uncontrolled diabetes, or severe stomach issues will not be able to participate.
Participants will receive the study medication, IAM1363, while doctors carefully check their safety and health. You will also have regular imaging scans like CT or MRI to see how your tumor responds to the treatment.
This study is currently active and recruiting participants at multiple locations, including centers in California and Colorado. Your care team will guide you through all the details if you are interested in joining.
- 1Testing a new medicine called IAM1363 for HER2-positive advanced cancers
- 2Open to adults whose previous cancer treatments have stopped working
- 3Currently recruiting patients at study locations in California and Colorado
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.